Group | | Post-challenge day (pcd) |
---|
0* | 2 | 4 | 7 | 10 | 15 | 30 | 63 |
---|
A | gE-ELISAa | − | − | − | − | − | − | + | + |
gB-ELISAb | + | + | + | + | + | + | + | + |
ELISAc | − | − | − | − | − | − | + ^ | + ^ |
B | gE-ELISAa | − | − | − | − | − | − | + | + |
gB-ELISAb | − | − | − | − | + | + | + | + |
ELISAc | − | − | − | − | − | + ^ | + ^ | + ^ |
- *The day of challenge corresponding to 270 pvd; A, Vaccinated group; B, Control group.
- aIDEXX IBR gE Ab test, MAINE, USA. This test detects antibodies to glycoprotein E (gE) of BoHV-1/BuHV-1.
- bIDEXX IBR gB X3 Ab, Maine, USA. This test detects antibodies to glycoprotein B (gB) of BoHV-1/BuHV-1.
- cIN3Diagnostic Eradikit™ BoHV-1-BuHV-1 discrimination kit, Turin, Italy. This test discriminates antibodies to glycoprotein E (gE) against BoHV-1 and BuHV-1. NA, + ^, positive to BuHV-1.